Search

everythinglearnresearchcommunity

for

Search:↓

In alopecia areata, certain immune cells increase and express a protein linked to immune activation.

New drugs targeting the JAK-STAT pathway show promise for treating inflammatory skin diseases.

Higher levels of IL-1a and IL-1RA were found in severe alopecia areata cases.

New insights into cell communication in psoriasis suggest innovative drug treatments.

Exercise-induced particles can slow breast cancer growth by boosting immune response.

COVID-toes show a unique immune response over time, different from vaccine-related chilblains.

IL-4 and IL-13 might play a role in a type of hair loss similar to alopecia areata.

Laminin-511 may contribute to psoriasis by affecting skin cell growth and survival.

Blocking IL-12/IL-23 does not help with hair loss in alopecia areata for mice or humans.

LRIG1 is linked to better survival in Merkel cell carcinoma.

ILC1-like cells can independently cause alopecia areata.

Pimecrolimus boosts melanin production and movement of skin pigment cells.

Blocking TSLP reduces skin inflammation and cell overgrowth in psoriasis.

Collagen XVII and CD151 affect cell movement, with CD151 inhibiting migration when bound to integrins.

Special immune cells called Tregs can help prevent lung scarring by blocking a specific growth factor.

Secukinumab reduces immune activity in hidradenitis suppurativa skin.

Inflammation is linked to hair loss.

Blocking certain proteins can significantly regrow hair in severe alopecia areata.

Increasing type 17 collagen reduces aging signs in skin cells caused by UV light.

People with acne have more CD4+ immune cells in their skin than healthy people.

RNase L hinders hair follicle regeneration by altering immune signals.

Ustekinumab significantly improved psoriasis, vitiligo, and alopecia areata in a patient.

The research developed methods to test drugs that could protect and restore hair follicle protection in a hair loss condition.

Immunomodulatory therapies are effective for treating cutaneous lymphoma, particularly in early stages.

JAK inhibitors are effective in treating various immune-related diseases, not just rheumatoid arthritis.

Interferon, especially alfa interferon, is an effective treatment for cutaneous T-cell lymphoma with manageable side effects.

PDRN may reduce inflammation and complications in revision rhinoplasty for patients with high fibrinogen levels.

A fragment of human type XVII collagen shows great potential for skin health and wound healing.